| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.ATHEROSCLEROSIS.2013.07.052 |
| P698 | PubMed publication ID | 24075754 |
| P50 | author | Raimund Erbel | Q29999865 |
| Mouaz Al-Mallah | Q37828820 | ||
| Matthew J Budoff | Q40403049 | ||
| Andrei C. Sposito | Q41717703 | ||
| Khurram Nasir | Q75515424 | ||
| Michael J Blaha | Q88645300 | ||
| Ron Blankstein | Q90238982 | ||
| Ricardo C Cury | Q106827517 | ||
| P2093 | author name string | Arthur S Agatston | |
| Ted Feldman | |||
| Raul D Santos | |||
| Jonathan Fialkow | |||
| Ebenezer T Oni | |||
| P433 | issue | 2 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 258-267 | |
| P577 | publication date | 2013-08-09 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? | |
| P478 | volume | 230 |
| Q49834000 | A High-Fat and High-Cholesterol Diet Induces Cardiac Fibrosis, Vascular Endothelial, and Left Ventricular Diastolic Dysfunction in SHRSP5/Dmcr Rats |
| Q35855651 | A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study |
| Q93078355 | A Review of Cardiovascular Toxicity of Microcystins |
| Q37664577 | Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. |
| Q52631894 | Association Between Nonalcoholic Fatty Liver Disease and Severe Male Reproductive Organ Impairment (Germinal Epithelial Loss): Study on a Mouse Model and on Human Patients. |
| Q40080468 | Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test |
| Q36336631 | Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women |
| Q90132513 | Association of Fetuin-B with Subclinical Atherosclerosis in Obese Chinese Adults |
| Q55284310 | Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)-cause for concern? |
| Q91562298 | Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model |
| Q57161282 | Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States |
| Q47552543 | Cardiometabolic risk in obese children |
| Q39692793 | Cardiovascular Autonomic Dysfunction in Patients of Nonalcoholic Fatty Liver Disease |
| Q38711424 | Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease |
| Q90734876 | Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review |
| Q27010592 | Cardiovascular dysfunction in patients with liver cirrhosis |
| Q28085227 | Causes of changes in carotid intima-media thickness: a literature review |
| Q47581786 | Clinical relevance of liver histopathology and different histological classifications of NASH in adults |
| Q64254431 | Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? |
| Q50005286 | Comparison of carotid intima-media thickness and coronary artery calcium score for estimating subclinical atherosclerosis in patients with fatty liver disease |
| Q36952218 | Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. |
| Q55266683 | Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). |
| Q54760091 | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? |
| Q40893622 | Correlation between nonalcoholic fatty liver and cardiovascular disease in elderly hemodialysis patients. |
| Q40670750 | Correlations of non-alcoholic fatty liver disease and serum uric acid with subclinical atherosclerosis in obese Chinese adults |
| Q64060477 | Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume |
| Q38261236 | Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. |
| Q46566732 | Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis. |
| Q91670378 | Diagnostic and prognostic biomarkers for the screening of patients with metabolic liver disease risk |
| Q55497819 | EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. |
| Q60462090 | EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease |
| Q37057956 | Elevated Glucose Oxidation, Reduced Insulin Secretion, and a Fatty Heart May Be Protective Adaptions in Ischemic CAD. |
| Q28081614 | Emerging risk biomarkers in cardiovascular diseases and disorders |
| Q49788822 | Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. |
| Q92722364 | Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease |
| Q36401621 | Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality |
| Q28079826 | Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV |
| Q38915869 | Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects |
| Q39105659 | Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1. |
| Q37615518 | Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study |
| Q35126823 | Hepatokines as a Link between Obesity and Cardiovascular Diseases |
| Q39377977 | Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance |
| Q35683422 | High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial |
| Q50550209 | Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. |
| Q36581177 | In Acute Myocardial Infarction Liver Parameters Are Associated With Stenosis Diameter. |
| Q36978865 | Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study |
| Q34635257 | Is serum Interleukin-17 associated with early atherosclerosis in obese patients? |
| Q33791133 | Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop |
| Q89687399 | Liver parameters as part of a non-invasive model for prediction of all-cause mortality after myocardial infarction |
| Q64939229 | Liver stiffness and arterial stiffness/abnormal central hemodynamics in the early stage of heart failure. |
| Q48607503 | Low-dose attenuation correction in diagnosis of non-alcoholic fatty liver disease |
| Q26750955 | NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? |
| Q90599751 | NAFLD and cardiovascular disease |
| Q91795147 | Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations |
| Q33706265 | Non-alcoholic fatty liver disease and cardiovascular risk |
| Q40593113 | Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study |
| Q94479096 | Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance |
| Q93379612 | Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden |
| Q55360071 | Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. |
| Q36937278 | Nonalcoholic Fatty Liver Disease is Associated with Increased Carotid Intima-Media Thickness in Type 1 Diabetic Patients |
| Q28079077 | Nonalcoholic fatty liver disease - A multisystem disease? |
| Q38592767 | Nonalcoholic fatty liver disease - current status and future directions |
| Q34366861 | Nonalcoholic fatty liver disease and aging: epidemiology to management. |
| Q27692035 | Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. |
| Q35903742 | Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study |
| Q55180178 | Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. |
| Q35258097 | Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c |
| Q42695154 | Nonalcoholic fatty liver disease: Evolving paradigms. |
| Q36673799 | Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival |
| Q35928495 | Pathogenesis of nonalcoholic steatohepatitis |
| Q36656294 | Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease |
| Q35926253 | Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review |
| Q53024874 | Prevention of Carotid Artery Atherosclerosis: What is the Evidence? |
| Q52985248 | Relationship of hepatic steatosis severity and coronary artery disease characteristics assessed by coronary CT angiography. |
| Q35670773 | Retracted: Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet |
| Q36769687 | Role of γ-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease |
| Q38676257 | The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. |
| Q47891372 | The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection |
| Q26746947 | The Natural Course of Non-Alcoholic Fatty Liver Disease |
| Q92482666 | The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis |
| Q100994717 | The metabolic basis of nonalcoholic steatohepatitis |
| Q44087796 | Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. |
Search more.